ArticleCerebellum (London, England)2025
Radiomics-based Modelling Unveils Cerebellar Involvement in Parkinson's Disease.
Article in Cerebellum (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Emerging pathological and neurophysiological evidence has highlighted the cerebellum's involvement in Parkinson's disease (PD). This study aimed to explore the potential of cerebellum-derived magnetic resonance imaging (MRI) radiomics in distinguishing PD patients from healthy controls (HC). A retrospective analysis was conducted using three-dimensional-T1 MRI data (n= 374) from the Parkinson's Progression Markers Initiative (PPMI) dataset (n= 204) and an independent in-house cohort (n= 170). Radiomic features (n= 883) were extracted from the cerebellar gray and white matter of each individual. Three machine learning models were developed: a cerebellar gray matter model, a cerebellar white matter model, and a combined gray and white matter model, to classify PD patients and HC. The results showed that the cerebellar gray matter model achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 0.931 in the training set, with a sensitivity of 60.8% and specificity of 97.1%, while in the testing set, it obtained an AUC of 0.874, with a sensitivity of 86.1% and specificity of 62.6%. The white matter-based model demonstrated an AUC of 0.846 (sensitivity, 59.8%; specificity, 87.3%) in the training set and an AUC of 0.868 (sensitivity, 81.0%; specificity, 75.8%) in the testing set. Notably, the combined gray and white matter model exhibited superior performance, achieving an AUC of 0.936 (sensitivity, 65.7%; specificity, 96.1%) in the training set and an AUC of 0.881 (sensitivity, 82.3%; specificity, 63.7%) in the testing set. Key radiomic features contributing to PD classification included Gray-level Dependence Matrix, Gray-level Co-occurrence Matrix and First-Order from gray matter, as well as Gray-level Size Zone Matrix from white matter, highlighting significant radiomics changes in the cerebellum associated with PD. In conclusion, this study demonstrates that MRI radiomics of cerebellar gray and white matter can effectively differentiate PD patients from HC, supporting the cerebellum's pivotal role in PD pathology and its potential as an imaging biomarker for PD.
Indexed as
Identifiers
39964592What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.